E-Cigarette Smoking History Tied to Increased Bladder, Lung Cancer Risk
Findings demonstrated that all smoking histories were tied to a higher prevalence of bladder and lung cancer.
ASCO GU 2022
Conference Coverage
Bladder-Sparing Therapies for Localized Muscle-Invasive Bladder Cancer Compared
The real-world study compared the efficacy of neoadjuvant chemotherapy plus immunotherapy vs chemotherapy alone in patients with cT2-4bN0-3M0-1a pathological and imaging diagnosed MIBC.
Immune Checkpoint Inhibitor Combo Therapy Assessed in mRCC Patients With Poor Performance Status
Since patients with poor PS (≥2) were excluded from trials analyzing this new standard of care for mRCC treatment, the study aimed to assess the efficacy and safety of immune checkpoint combination therapy in this group of patients.
Niraparib With Abiraterone + Prednisone Improves Outcomes in HRR BM+ Metastatic Castration Resistant Prostate Cancer
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
Talabostat Plus Pembrolizumab Promising for mCRPC With Adenocarcinoma Phenotype
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
Anxiety, Depression Med Use Linked to Increased Odds of PSA Testing
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
Serologic Outcomes Following COVID-19 Vaccination Assessed in Patients With Genitourinary Cancer
The study included a total of 183 patients with genitourinary cancers.
Study Identifies Treatment Preferences in Advanced Renal Cell Carcinoma
The case-based study aimed to analyze the prescribing behaviors of community oncologists treating patients with aRCC.
Long-Term Data Support Avelumab as First-Line Maintenance in Advanced Urothelial Carcinoma
Patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy were included in the analysis.
Sacituzumab Govitecan Plus Pembrolizumab Promising for Metastatic Urothelial Cancer After Failure With Platinum-Based Regimen
Cohort 3 of the phase 2 TROPHY-U-01 trial evaluated sacituzumab govitecan plus pembrolizumab in checkpoint inhibitor-naive adults with metastatic urothelial cancer who progressed after platinum-based chemotherapy.
Pharmacotherapies for First-Line Treatment of mCSPC Explored
The network meta-analysis aimed to compare various combinations of treatment options to determine the safest and most effective management strategy for mCSPC.
Statin Use Not Associated With Survival Benefits in mCRPC Patients
The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.
Continued Enzalutamide Tx Beneficial in mCRPC Patients With Progressive Disease
The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.
Pembrolizumab Plus Lenvatinib Not Superior to Pembrolizumab Alone in Advanced Urothelial Carcinoma
The phase 3 LEAP-011 study evaluated pembrolizumab plus lenvatinib vs placebo in 441 adults with histologically confirmed, locally advanced or metastatic urothelial carcinoma.
Real-World Data Confirm Pazopanib as Safe, Effective in mRCC
Investigators conducted a noninterventional, multicenter study (APOLON) in patients receiving frontline pazopanib therapy.
Relugolix Effective, Safe in Black Men With Advanced Prostate Cancer
Study authors analyzed a total of 46 Black men with advanced prostate cancer enrolled in the phase 3 HERO study.
Want to read more?
Please login or register first to view this content.